Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Falanga, A.
Right arrow Articles by Barbui, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Falanga, A.
Right arrow Articles by Barbui, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

A new procoagulant in acute leukemia

A Falanga, MG Alessio, MB Donati and T Barbui

Istituto di Ricerche Farmacologiche Mario Negri, Milano.

To verify whether cancer procoagulant (CP), a cysteine proteinase procoagulant distinct from tissue factor (TF), is associated with leukemic cells, we assayed the procoagulant activity of blast cell extracts from 26 patients with different cytological subtypes of acute nonlymphoid leukemia (ANLL) according to the French-American-British classification. All the samples except two shortened the recalcification time of normal human plasma, the effect being significantly greater in the M3 subgroup. The two criteria used to distinguish between CP and TF, independence from factor VII in initiating blood coagulation and sensitivity to cysteine-proteinase inhibitors, were positive in 19 samples from M1, M2, M3, and M4 cytological subtypes. None of the M5 samples fulfilled these criteria. In addition, M1, M2, M3, and M4 samples immunoreacted with an anti-CP goat polyclonal antibody on an Ouchterlony immunodiffusion plate. This study provides the first evidence for a procoagulant other than TF that is associated with leukemic cells.

Volume 71, Issue 4, pp. 870-875, 04/01/1988
Copyright © 1988 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 CLIN APPL THROMB HEMOSTHome page
M. Adess, R. Eisner, S. Nand, J. Godwin, H. L. Messmore Jr, and W. H. Wehrmacher
Thromboembolism in Cancer Patients: Pathogenesis and Treatment
Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 254 - 266.
[Abstract] [PDF]

Home page
 BloodHome page
A. Falanga, R. Consonni, M. Marchetti, G. Locatelli, E. Garattini, C. G. Passerini, S.G. Gordon, and T. Barbui
Cancer Procoagulant and Tissue Factor Are Differently Modulated by All-trans-Retinoic Acid in Acute Promyelocytic Leukemia Cells
Blood, July 1, 1998; 92(1): 143 - 151.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Barbui, G. Finazzi, and A. Falanga
The Impact of All-trans-Retinoic Acid on the Coagulopathy of Acute Promyelocytic Leukemia
Blood, May 1, 1998; 91(9): 3093 - 3102.
[Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1988 by American Society of Hematology         Online ISSN: 1528-0020